When several of the world’s biggest private equity (PE) firms start circling over a diagnostics company in Kerala, it is worth paying attention. Warburg Pincus, TA Associates, Bain Capital, and CVC Capital are among global private equity firms in early-stage discussions to buy about 25% stake in Agappe Diagnostics, ET reported today based on information from sources. The proposed deal is likely to value Kochi-headquartered Agappe, counted among India’s top in-vitro diagnostics (IVD) firms, at Rs 3,000-3,200 crore.
The PE race for a piece of Agappe Diagnostics is the latest sign that global investors are widening their search for healthcare opportunities in India. Until recently, most of the action was concentrated in hospitals. Today, capital seems to be moving deeper into the healthcare ecosystem, from speciality-care chains and fertility clinics to diagnostics manufacturers and medical technology companies. The result is a healthcare investment boom that is becoming one of the defining themes in Indian private equity.
A frenzy for healthcare assets
There is fierce competition currently underway for healthcare assets. In June, a clutch of global buyout firms including Warburg Pincus, KKR, Advent International, TPG Capital, CVC Capital Partners and Permira emerged as contenders for a 25% stake in Cloudnine, India’s largest maternity and paediatric hospital chain, ET had reported based on sources. The transaction is expected to value the company at around Rs 11,000 crore. As per people familiar with the matter. Cloudnine generated approximately Rs 2,000 crore in revenue and Rs 300 crore in EBITDA in FY26, making it one of the most sought-after healthcare assets in the market.The significance of the bidding wars goes beyond valuations. It shows the willingness of global investors to compete aggressively for minority stakes in quality healthcare platforms. A decade ago, private equity firms were often looking for control transactions or distressed opportunities. Today, they are prepared to pay premium valuations simply to gain exposure to healthcare growth. That change says a great deal about how the sector is now viewed.
Unlike sectors that are heavily dependent on economic cycles, healthcare demand tends to be resilient. For private equity firms managing billions of dollars, that predictability has become increasingly valuable.
Why this cycle is different
Healthcare has attracted investment before, but the current wave is being driven by a different set of fundamentals. Over the past few years, many hospital operators focused on strengthening balance sheets, reducing debt and improving profitability. Occupancy rates rose steadily while leverage came down. The sector has now entered a new phase in which operators are once again investing heavily in expansion. Investors are responding because demand continues to outpace supply. India remains one of the most under-served healthcare markets among major economies. Hospital bed availability remains far below global averages, while rising incomes, increasing insurance penetration, longer life expectancy and growing incidence of chronic diseases continue to expand demand for organised healthcare services.
IPOs change the equation
Another reason for the surge in investor interest could be that healthcare now offers clearer exit opportunities. One of the biggest developments this year has been Manipal Health Enterprises moving closer to what could become one of India’s largest healthcare listings. The company has received regulatory approval for an IPO that could raise as much as $1.2 billion. The proceeds will partly be used to reduce debt and support expansion following its acquisition of Sahyadri Hospitals. The importance of the Manipal IPO extends beyond the company itself. It shows that public markets are willing to absorb large healthcare offerings. For private equity investors, that dramatically improves the attractiveness of the sector.
Healthcare was once viewed as a market where exits could be difficult and timelines uncertain. The emergence of a credible IPO pipeline changes that calculation. Investors can now see multiple pathways to monetisation, whether through public listings, strategic sales or secondary transactions. The result is a market where capital is flowing more freely than before.
Speciality care is the sweet spot
One of the clearest trends in recent years has been the rise of focused healthcare platforms. Cloudnine is a good example. Rather than operating as a traditional multi-speciality hospital chain, it built a business around women’s and child healthcare. Similar investor interest is visible across fertility, oncology, eye care, nephrology and other speciality segments. Private equity firms like these businesses because they combine strong growth with relatively clear positioning. They are often able to build stronger brands, command higher margins and expand more efficiently than general hospital operators. The trend is also visible in the growing number of speciality healthcare companies exploring public market listings. Eye-care chains, fertility networks and focused healthcare providers are increasingly attracting institutional capital that would once have been reserved for large hospital groups.
Diagnostics is emerging as the next frontier
For years, discussions around healthcare investing largely revolved around hospital beds, doctor networks and patient volumes. Diagnostics was viewed as an important but relatively narrow segment. That perception is changing now. The pandemic fundamentally altered the visibility of diagnostics. Testing became central to healthcare delivery. Since then, awareness of preventive healthcare has increased sharply. More Indians are undergoing routine health screenings. Chronic disease management requires frequent monitoring. Specialised testing is becoming more common in oncology, cardiology and precision medicine.
All of these trends are expanding the diagnostics market. What makes the sector especially attractive to investors is that opportunities now extend beyond pathology chains. Capital is increasingly looking at the broader diagnostics ecosystem, including laboratory technology, diagnostic consumables, test kits and in-vitro diagnostics manufacturing. Agappe is one of the leaders within this emerging theme. The company operates in the IVD and diagnostics manufacturing space, an area that benefits from rising testing volumes while also aligning with India’s push towards domestic healthcare manufacturing. The interest from multiple global private equity firms suggests investors see the potential to build scaled healthcare businesses far beyond the traditional hospital model.
In many ways, diagnostics offers investors exposure to healthcare growth without some of the operational complexity associated with running hospitals. Demand is recurring, technology adoption is increasing, and opportunities for product innovation remain significant. That combination can be difficult to ignore.
Capital moving beyond metro markets
Another reason healthcare continues to attract private equity is that the opportunity is no longer confined to India’s largest cities. Many investors now see substantial growth potential in tier-2 and tier-3 markets where healthcare infrastructure remains inadequate relative to demand. Organised hospital chains, speciality-care operators and diagnostics companies are all expanding into these regions. Rising incomes and greater health awareness are increasing demand for quality healthcare, while organised supply remains limited. Investors believe this gap will support years of growth. That is one reason why acquisition activity and expansion plans remain so aggressive despite already elevated valuations.
The investment story expands
In Indian healthcare today, there is a steady expansion of investor interest across the sector. A few years ago, private equity firms were largely focused on hospitals. Today they are evaluating speciality-care platforms, fertility chains, eye-care networks, healthcare technology businesses and diagnostics manufacturers. The universe of investable healthcare assets has become much larger. The Agappe discussions reveal where investors are looking next.
Though hospitals remain the largest destination for capital, as competition intensifies and valuations climb, private equity firms can move into adjacent segments that can ride the same healthcare growth story. Diagnostics and IVD manufacturing appear to be among the biggest beneficiaries of that shift. The quiet boom in Indian healthcare is no longer confined to hospital corridors. It is spreading across the entire healthcare value chain, and global investors seem determined not to miss it.
